Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

眼部炎症中的玻璃体蛋白质组和炎症介质

• 批准号: 7975936
• 负责人: DARBY THOMPSON
• 金额: $ 13.93万
• 依托单位: THE EMMES COMPANY, LLC
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-11-01 至 2011-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7975936
• 关键词: Vitreous; Proteome; Inflammatory; Mediators; Ocular

This study will examine the proteins of people with uveitis, or inflammation of the eyes. Evaluating the vitreous, the colorless transparent substance that fills the eyeball in back of the lens, is now possible with the use of new microtechnology. There is an opportunity to evaluate the kinds of proteins that are present in severe, noninfectious sight-threatening uveitis. Patients ages 18 and older who have been enrolled in the Multicenter Uveitis Steroid Treatment (MUST) study at NIH may be eligible for this study. Up to 200 patients eventually may be enrolled. Researchers will study the vitreous that will be removed from patients' eyes during an operation to insert a steroid implant. The steroid implant is used instead of immunosuppressive therapy, a way to reduce the action of the immune system. Patients will undergo a procedure involving a small hole made in the eye into which the implant is placed. Normally a small amount of the vitreous comes out during that procedure, and in this study, the vitreous specimen will be taken for testing of inflammatory products. At the same time, a small sample of blood, about 1-1/2 tablespoons, will be collected so that the researchers can compare inflammatory products that may be in the blood with those in the vitreous. If a patient needs to have the implant placed again during the study, he or she would be asked permission for collection of the vitreous and blood samples, as previously. Samples collected will not be used to diagnose patients' conditions or to change any treatments being done. All samples will be labeled with special code numbers so that there is no identifying information about patients. This study will not involve examinations or scheduled visits of patients.

这项研究将检查葡萄膜炎患者的蛋白质或眼睛炎症。现在可以使用新的微技术来评估玻璃体透明的玻璃体，无色的透明物质。有机会评估严重的，非感染的视力威胁性葡萄膜炎中存在的蛋白质。 在NIH进行多中心葡萄膜炎治疗（必须）研究的18岁及以上的患者可能有资格参加这项研究。最终可能会招募200名患者。研究人员将研究手术期间将从患者眼中移除的玻璃体，以插入类固醇植入物。使用类固醇植入物代替免疫抑制治疗，这是减少免疫系统作用的一种方法。 患者将接受一项涉及植入物中的小孔的手术。通常，在此过程中，少量玻璃体出现，在这项研究中，将采用玻璃体标本来测试炎症产物。同时，将收集一小部分血液样本，约1-1/2汤匙，以便研究人员可以将可能的血液中的炎症产物与玻璃体中的炎症产物进行比较。如果患者在研究期间需要再次放置植入物，则像以前一样，他或她将被要求收集玻璃体和血液样本。收集的样本将不用于诊断患者状况或更改正在进行的治疗方法。所有样品将标记为特殊代码编号，因此没有有关患者的识别信息。这项研究将不涉及患者的检查或预定访问。